Table 4 Studies investigating prognostic value of miR-210
From: Multiple functions of hypoxia-regulated miR-210 in cancer
First author | Publication year | Types of cancer | Types of sample | RR or HR (high VS low expression level) |
|---|---|---|---|---|
Camps [16] | 2008 | Breast cancer | tissue | 4.07(PFS), 11.38(OS) |
Lawrie [90] | 2008 | Diffuse large B-cell lymphoma | serum | No significance |
Gee [17] | 2010 | Head and neck cancer | tissue | Not provided |
Greither [82] | 2010 | Pancreatic cancer | tissue | 2.48 |
Buffa [107] | 2011 | Breast cancer (ER−) | tissue | Not provided |
Radiojicic [78] | 2011 | Triple-negative breast cancer | tissue | No significance |
Rothe [80] | 2011 | Breast cancer | tissue | 4.43(RFS) |
Greither [104] | 2012 | Soft-tissue sarcoma | tissue | 3.19(PFS)* |
Toyama [79] | 2012 | Breast cancer | tissue | 4.39 |
Volinia [105] | 2012 | Breast cancer | tissue | 1.54(OS) |
Cai [91] | 2013 | Pediatric osteosarcoma | tissue | 2.6(PFS), 3.3(OS) |
Eilertsen [87] | 2013 | Non-small cell lung cancer | tissue# | 1.9(DSS)** |
McCormick [23] | 2013 | Renal cancer | tissue | Not provided |
Qiu [106] | 2013 | Glioblastoma | tissue | 0.75** |